Wire · regulatory
Pfizer Nets Another FDA Approval for Talzenna, Xtandi in Prostate Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
The US FDA approved Pfizer's Talzenna (talazoparib) combined with Xtandi (enzalutamide) for treating metastatic prostate cancer patients with homologous recombination repair gene mutations, targeting androgen pathway modulation-naïve or -sensitive cases.
This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it.
◆ ◆ The Wire takeaway
You can now expand prostate cancer treatment offerings by integrating the combined Talzenna and Xtandi therapy, which opens new patient segments with specific gene mutations. This approval demands timely adjustment to clinical strategies and patient targeting to capitalise on this FDA expansion.
◆ Coverage
7 sources · 26 Oct 2026
◆ Related on Wire
◆ Topics